Company Oasmia Pharmaceutical AB NORDIC GROWTH MARKET
Equities
OASM
SE0000722365
Pharmaceuticals
Business Summary
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 26 | 100.0 % | 1 | 100.0 % | -96.12% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Other Countries
100.0
%
| - | - | 1 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Johanna Röstin
LAW | General Counsel | 57 | 21-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Roger Tell
BRD | Director/Board Member | 59 | 22-05-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 538,043,000 | 330,469,658 ( 61.42 %) | 0 | 61.42 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |